Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti‐CD3ε mAb in new‐onset type 1 diabetes mellitus patients-Reference-Cited by-同舟云学术

Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti‐CD3ε mAb in new‐onset type 1 diabetes mellitus patients

Published:2019-02-05 Issue:4 Volume:85 Page:704-714
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Vlasakakis Georgios¹^ORCID,Napolitano Antonella¹,Barnard Ruth¹,Brown Kim²,Bullman Jonathan¹,Inman David¹,Keymeulen Bart³,Lanham David⁴,Leirens Quentin⁵,MacDonald Alexander⁶,Mezzalana Enrica⁵,Page Kevin¹,Patel Minesh⁴,Savage Caroline O.¹,Zamuner Stefano¹,Maurik Andre¹

Affiliation:

1. Research and DevelopmentGlaxoSmithKline London UK

2. Project ManagementGlaxoSmithKline London UK

3. Academic Hospital and Diabetes Research CenterVrije Universiteit Brussel Brussels Belgium

4. Eurofins Pharma Bioanalysis Services UK Ltd

5. SGS Exprimo NV Generaal de Wittelaan 19A b5 B‐2800 Mechelen Belgium

6. Oncology Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech UnitAstrazeneca Cambridge UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link